

# Recce Pharmaceuticals

Up to A\$85m of overseas R&D funding secured

R&D funding secured

Healthcare

18 December 2025

Recce Pharmaceuticals recently reported that the Australian government has agreed to provide it with up to A\$85m in future cash rebates over the next three years to reimburse the company's upcoming R&D expenditure towards its proprietary synthetic anti-infective programmes. This binding Advanced Overseas Finding (AOF) agreement with the Australian government's Department of Industry, Science and Resources (AusIndustry) extends the rebate programme, which customarily reimburses 43.5% of eligible R&D expenditures incurred within Australia, to cover the anti-infective R&D activities Recce undertakes anywhere in the world. This is particularly noteworthy given that Recce started patient dosing in September 2025 for its pivotal Phase III Indonesian-focused study of its R327 topical gel formulation (R327G) for the treatment of diabetic foot infections (DFIs). We estimate the majority of this study's costs will be incurred outside of Australia, with this AOF decision therefore potentially benefiting Recce.

Year end	Revenue (AUDm)	PBT (AUDm)	EPS (AUD)	DPS (AUD)	P/E (x)	Yield (%)
6/24	4.9	(17.8)	(0.10)	0.00	N/A	N/A
6/25	7.0	(22.1)	(0.09)	0.00	N/A	N/A
6/26e	8.5	(27.2)	(0.09)	0.00	N/A	N/A
6/27e	9.8	(57.5)	(0.20)	0.00	N/A	N/A

Note: PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

This [AOF](#) awarded by AusIndustry is reported to be [one of the largest in Australian history](#) and we believe it signals that the Australian government continues to recognise the vital importance of developing novel anti-infective therapeutics to combat antimicrobial resistance. The added clarity from this AOF on the future reimbursement of overseas R&D activities is beneficial and helps de-risk future funding for Recce given our expectation that, in addition to the ongoing [Indonesian-focused Phase III DFI study](#), further clinical trials outside of Australia (and including US sites in particular) will be needed to maximise the commercial potential of R327 in areas such as acute bacterial skin and skin structure infections, sepsis and urosepsis and complicated urinary tract infections.

Separately, Recce [announced in November](#) that, as part of an ongoing research collaboration with Murdoch Children's Research Institute, R327 has shown substantial antibacterial activity in a preclinical hospital- and ventilator-associated pneumonia (HAP/VAP) mouse model study against carbapenem-resistant *Acinetobacter baumannii* (CRAB). CRAB can cause deadly infections and outbreaks in hospital settings. It is designated as an urgent public health threat by the [US Centers for Disease Control and Prevention](#) and as one of only three critical priority group pathogens by the [World Health Organization](#).

In the study, nebulised R327 showed a four-log reduction in CRAB (>99.99% lower burden) at 24 hours post-infection and preliminary reductions in pro-inflammatory indicators were also observed in the R327-treated groups. Importantly, the ability for R327 to be delivered through a nebuliser can potentially provide a more rapid and direct treatment for HAP/VAP in acute settings, should future studies also be supportive. Overall, the preclinical data for R327 in CRAB is highly encouraging in our view and boosts the potential breadth of R327's applicability in anti-infective indications.

**Price** **AUD0.590**  
**Market cap** **AUD171m**

Gross cash at 30 September 2025 AUD3.2m  
Shares in issue 289.2m  
Code RCE  
Primary exchange ASX  
Secondary exchange FSE

## Share price performance



## Business description

Recce Pharmaceuticals is an Australian company developing its novel, broad-spectrum synthetic polymer anti-infective drugs for the treatment of several infectious diseases, including sepsis, acute bacterial skin and skin structure infections, diabetic foot infections, burn wound infections and urinary tract infections.

## Analysts

Jyoti Prakash, CFA +44 (0)20 3077 5700  
Pooya Hemami, OD +44 (0)20 3077 5700  
MBA, CFA

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

[Edison profile page](#)

**Recce Pharmaceuticals is a research client of Edison Investment Research Limited**

---

### General disclaimer and copyright

This report has been commissioned by Recce Pharmaceuticals and prepared and issued by Edison, in consideration of a fee payable by Recce Pharmaceuticals. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

**Accuracy of content:** All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

**Exclusion of Liability:** To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

**No personalised advice:** The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

**Investment in securities mentioned:** Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2025 Edison Investment Research Limited (Edison).

---

### Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

---

### New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

---

### United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

---

### United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

---